Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Sep 28, 2020 3:47pm

365 Views

Post# 31630268

RE:A little PR for Stauffer and Antibe ...

Awesome......validating Dr. Stauffer's resume for Otenaproxesul's success of phase 2b/3..................load up peeps!

MrMugsy wrote: Certainly different than we are used to seeing.
Brings a little PR to Antibe.

23rd Evolution Summit – Best Practices in North American Clinical Trials

December 2 - 4, 2020 | Boston, MA

Summit will be chaired by Dr. Joseph Stauffer, Antibe’s Chief Medical Officer.

Topics will include:

Getting Back on Track: Moving past COVID-19 to regain successful trial operations and combat this new era of challenges

A Thrust into the Virtual World: Unlocking the full potential of siteless clinical trials, evaluating the opportunities and analyzing best practices

Riding the Digital Wave: Exploring new avenues for optimization through digitization and mapping the future of digital innovation

Tracking the Evolution of Remote Monitoring amidst COVID-19: Assuring successful implementation through the implementation of a solid, quality risk-based monitoring program

Recent and Relevant Changes in the Regulatory Environment: Significant trends in the current regulatory environment and the impact on strategies and strategic thinking

Creating a “New Normal” What Will Clinical Trials Look Like Post-COVID-19: Analyzing which changes were necessary and can be maintained to achieve higher levels of efficiency